Phase 2Update

Rilvegostomig (PD-1/TIGIT)

Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer

CGENCompugen

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Rilvegostomig (PD-1/TIGIT)
Development stage: Phase 2
Event type: Update
Indication: Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 2 update for Rilvegostomig (PD-1/TIGIT) in Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

08/03/26:- GEMINI-Hepatobiliary ASCO data showed 16.8-month median survival and manageable safety.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source